Authors
Loading...
Observational analysis showed improved cardiometabolic control in patients with type 2 diabetes on dapagliflozin, suggesting better outcomes than standard antidiabetic therapy.
Carratalá et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: